{"name":"iVeena Delivery Systems, Inc.","slug":"iveena-delivery-systems-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPOURLUFZqLWVPQmg0ZkxkdnhlcW9Vcmw4bkhqa0UwckV6WmdhQVRrSkU2ZllQREJiamYwMGZ4LWpVNmR0MGlyUVFKb1RxMmlNZTRnVjNza0h6QTdNR3p4OUoyV2tZSy1vZHhqQXJHVTQ0RGxvbVVndzZQSm9jTVhTaUxJb3dodDhOaDJlVUppZVo4TjRRZG93djR0THpNY2xFOE05T0pGUEp2NUh3Rm9yTFA3cmlObUMxamUtSjZQTlRnYlI5aHZncTFtaFZxeWRjTHV4NmpIQmxFdGQ4a0MxczNBTUNUOWtJbG5xaDZkQkxJQWlOSGlLZW9zMFc4TlloNnpLc2NOZElOeTFkQ21Zb2t1Vmh1eVY4T3VmQnExYVBQc0lGa1ZEUkFHdGI5SkkwRHFz?oc=5","date":"2026-03-17","type":"trial","source":"Mena FN","summary":"Myopia Pipeline 2026: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight Ziemer Group, NIDEK CO., LTD, 2Eyesvision, Carl Zeiss AG, Alcon, Coopervision, Topcon Healthcare - Mena FN","headline":"Myopia Pipeline 2026: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight Ziemer Group, NIDEK CO., L","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPMUhpdnYzMVBCaHZrUWxlVzZmUThGcnB5OGU0eEpKeXhCTkVaNU13S3phV0Rjd0hFTmYtTmxtc2pNaHRuMzlxaHFOb21BVVJRWnAxV1ZTNVlSblZLMU55dDdEY3Vac0dYcDlhVXZMVlVJVWZWZnZuWnVJMGY5emRtVVhLaC1MS0RpVndRTlR0V2tzbWs0Tmkza2NkbE1LUW5vSDVrc05hcXpKOXY4VDAyMVAtWVlYY0l6VWx0b290UDc4NllBX2dSTHZkbGtXYVFEM3lYRXYwUjZnMGpFMUtyelNySHU1RUpBWFd0SldWSW9ZVjVqSHI0cjhRQQ?oc=5","date":"2026-02-11","type":"trial","source":"Business Wire","summary":"iVeena Delivery Systems Announces First Patient Dosed in Phase 1 Study of IVMED-85 in Healthy Adult Volunteers - Business Wire","headline":"iVeena Delivery Systems Announces First Patient Dosed in Phase 1 Study of IVMED-85 in Healthy Adult Volunteers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxPOWkxNWViWERTMng0V0FRRHZ5NGxibHhSR0dORU0wV3ZoVldRU3VWUl9NMlJveVRvbGlKc1dXcWxWSlBhQm5PZDFDcVN4Yno3OVFaRHRVRXRmTk00RjZ6ek1VUXM2SzR3MHd6dGtjSDlobzc2R1o5MU5lWlFzQ2oyak5FUUFfLWhpUjJMZld3eWxuZThvYjdvbWoxZkdZRmRITVVpMmFNSHRIVU5ieXRYRldILWVrQ3lLa3h3alU5UHEyY1BKVGdEMjBmemhzYTNYeHZfaHpIUG05cVFQb1V1aDIwbWJ2QUUyeVY4NmZNVDNfdnhyU01pQkhJWU11UQ?oc=5","date":"2026-02-04","type":"pipeline","source":"Business Wire","summary":"iVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific Innovation - Business Wire","headline":"iVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific Innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxNN01XbHFia3FtZU1ZVlJ0TkFCS0NfZmQydkRSZ25tdHBoTGJHejlDX3F4VmZmcWV4ZmRfNDBMUjllZ3lmM0llcWI2MVVJYTZsdW1laGk3d3RXa2JBSGdob29pUE5lVnhWMlFYX0ZkVVpGY05BY2xFT3pNMTVUOVhBRm9KaU5feF80Nk1UTXQ3WWlIbFgzZFc2aXVZcE5FWVIzRURZYWJkUUFHd3ZUOEFCWGlOVDNwZklnMFpHX2hRaW9GdkVmb3RGZXExckl4d2V0Qm5FMHZfWjVObFNYVkFMUWpDc0FsS3BtaXFJWnJfUk4?oc=5","date":"2025-09-18","type":"pipeline","source":"Business Wire","summary":"iVeena Awarded $2 Million National Eye Institute Grant to Advance Novel Therapy for Pediatric Myopia - Business Wire","headline":"iVeena Awarded $2 Million National Eye Institute Grant to Advance Novel Therapy for Pediatric Myopia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPVkpyWnhCVl9sOFVKWFRpOW9OSEp6VjZqSDJUSXJEQ3hya19aLVRZWW5MMzRsR0hPTFMtSHZlX2tkNTBfOGFmcnVLeUoxNnIya3NUMVBfMHI2SlExR20xXzdhU29hNm1Bd3pXOVZ2cEUtZjYzWTRJZmxxU2VDTjhfR21rQmpUUFZqSUc0TkVJQTZzNGZ6em9aN2ZOb1pOTWZLSVRQdVhZYXAtQWl0a3g3Qw?oc=5","date":"2025-06-04","type":"regulatory","source":"Optometry Times","summary":"iVeena submits IND to FDA for a phase 2 clinical trial for pediatric myopia - Optometry Times","headline":"iVeena submits IND to FDA for a phase 2 clinical trial for pediatric myopia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNVDFrV3R4QU1QazZPUG13NGh4czFkTG1xQXdTTXRMNURKeWR0WnhEaDZ2bjJsTU5nSDQ1QndUS2FVam5rcW8ydjNMUXNLV09UZHpST0xmX2xKc1V4QUwtU1VkemVjUERScTJQYV9nUjFldTNLVkYxNHh2bzl5dEJUZXBoY0hDN0NXWTYwWHNheEJjMnltaWRON1JqNkVqQnhvV21lVlBqSHBpOEszR0loVG1qT3BjSTZoLXlHSVNqMnc4TFhFTnE4YUlkanFRMDluakhoa291bnUtbzZqUTVKX2JDMmJIalV0RFNMbF9n?oc=5","date":"2025-02-05","type":"pipeline","source":"Business Wire","summary":"iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia - Business Wire","headline":"iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-10-19","type":"trial","source":"PR Newswire","summary":"Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies - Nevakar, Vyluma, Bausch & Lomb, Sydnexis, Ocumension, ORA, LENZ Ther","headline":"Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE5SWnQzWk02WnoxQllyc1Znb1Rkek1jd1Y3RGwtNi1vcFB1MVFVYkxGSWlVMHhJZnhvb2QwUElIQ0ktSkxha2V1emZFU1Q5eDZnbGduTmQ0WUx3MjdVS3Y5XzVXYkttYW01Y0VuY19maFk?oc=5","date":"2022-09-02","type":"pipeline","source":"EyeWorld","summary":"EyeWorld Weekly, September 2, 2022 - EyeWorld","headline":"EyeWorld Weekly, September 2, 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOcll2bEdQc09ON3BuZEt4bEZ4YjQzNkNHTHlHdlpIR1BnbFNURy1PTm9uVk5aX3VVRk1JQ3RrMVVnMUxYNUxOMG1aT0lRcjVUYl9pS253ajFfaUlHNWxrT3lWdTdkYjNuLW1BQTlDT0xDd3VKcWk4cWV2NXBOZFFYWXVWMWMzaTZReW9KXzlTeFRodVRa?oc=5","date":"2022-08-30","type":"pipeline","source":"Fierce Pharma","summary":"Glaukos pays iVeena $10M for eye drop vision loss candidate - Fierce Pharma","headline":"Glaukos pays iVeena $10M for eye drop vision loss candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQS1daYXdxbTBJTXNQOE5qaHVXRjJEY2YtdlNvcDQwTENxUEhaOER2RVlPNmNXSVVtSUY5XzU1bEkxR2dlc01xTm42bVV3Qnl2czhPRjNwZXhNZThzYUpzMHplTVFidHp3allZNkFhZjZERGtTQVpWallHX2dWRWpfUldVeU1sT01BWnR1MUlpa0JPS2RTbU5tejJBTHhhTk5IYXVXUVhSNGVIWXoxRXE1aDZTSU9NVVly?oc=5","date":"2022-08-24","type":"deal","source":"Business Wire","summary":"Glaukos Licenses Iveena’s Investigational Keratoconus Therapy - Business Wire","headline":"Glaukos Licenses Iveena’s Investigational Keratoconus Therapy","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}